N-Boc-(2’-氯苯基)甘氨酸 | 313490-25-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-Boc-(2’-氯苯基)甘氨酸
• 中文别名: N-BOC-(2'-氯苯基)甘氨酸；N-Boc-(2'-氯苯基)甘氨酸；N-boc-(2-氯苯基)甘氨酸
• 英文名称: [(tert-butoxycarbonyl)amino](2-chlorophenyl)acetic acid
• 英文别名: N-Boc-(RS)-2-chlorophenylglycine；2-chloro-α-[[(1,1-dimethylethoxy)carbonyl]amino]-benzeneacetic acid；N-Boc-(2'-Chlorophenyl)glycine；2-(2-chlorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid
• CAS: 313490-25-4
• 化学式: C₁₃H₁₆ClNO₄
• 分子量: 285.727
• InChiKey: XPFJZGJBRMTXCE-UHFFFAOYSA-N

物化性质

• 沸点：
  431.5±40.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  N-Boc-(2’-氯苯基)甘氨酸 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  The Discovery of N-((2H-Tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist

  摘要：

  A novel series of spiroimidazolone-based antagonists of the human glucagon receptor (hGCGR) has been developed. Our efforts have led to compound 1, N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822), a potent hGCGR antagonist with exceptional selectivity over the human glucagon-like peptide-1 receptor. Oral administration of 1 lowered 24 h nonfasting glucose levels in imprinting control region mice on a high fat diet with diet-induced obesity following single oral doses of 3 and 10 mg/kg. Furthermore, compound 1, when dosed orally, was found to decrease fasting blood glucose at 30 mg/kg in a streptozotocin-treated, diet-induced obesity mouse pharmacodynamic assay and blunt exogenous glucagon-stimulated glucose excursion in prediabetic mice.

  DOI：

  10.1021/jm401858f
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 o-chlorophenylglycine 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 以89%的产率得到N-Boc-(2’-氯苯基)甘氨酸
  参考文献：
  名称：

  Chemo-enzymatic approach to the synthesis of the antithrombotic clopidogrel

  摘要：

  The (S)-2-chlorophenylglycine moiety is well recognized in the structure of (S)-clopidogrel, a known antithrombotic drug. We prepared an enantiomerically pure chiral building block via an enzyme-catalyzed resolution of (RS)-N-Boc-2-chlorophenylglycine methylester. The best results were obtained by means of an immobilized subtilisin, the cross-linked enzyme aggregate (Alcalase-CLEA (R)). The high enantiomeric excess of the synthon obtained remained the same over the course of clopidogrel synthesis; the simplicity of the process makes this pathway suitable for large-scale preparation. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2010.06.040

文献信息

• [EN] NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE<br/>[FR] NOUVELLES SPIRO-IMIDAZOLONES EN TANT QU'ANTAGONISTES DE RÉCEPTEUR DE GLUCAGON, COMPOSITIONS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011119559A1

  公开（公告）日：2011-09-29

  The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

  本发明涉及一般式化合物，其中环A、环B、R1、R3、Z、L1和L2彼此独立选择，并如本文所定义，涉及包含该化合物的组合物，以及使用该化合物作为胰高血糖素受体拮抗剂以及用于治疗或预防2型糖尿病及相关疾病的方法。
• SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF
  申请人：Fürstner Chantal

  公开号：US20130231313A1

  公开（公告）日：2013-09-05

  The present application relates to novel substituted phenylacetamides and phenylpropanamides, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型取代苯乙酰胺和苯丙酰胺，以及用于制备它们的方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。
• [EN] PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS<br/>[FR] PYRROLIDINE-PYRAZOLES EN TANT QU'ACTIVATEURS DE LA PYRUVATE KINASE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021202796A1

  公开（公告）日：2021-10-07

  The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

  本文描述的主题是针对式I的丙酮酸激酶激活化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物以及用于治疗与PKR和/或PKM2相关疾病的化合物的给药方法，例如丙酮酸激酶缺乏症、镰状细胞病和β地中海贫血。
• Chemo-Enzymatic Dynamic Kinetic Resolution of Amino Acid Thioesters
  作者：Dario Arosio、Antonio Caligiuri、Paola D'Arrigo、Giuseppe Pedrocchi-Fantoni、Cristina Rossi、Caterina Saraceno、Stefano Servi、Davide Tessaro

  DOI：10.1002/adsc.200700050

  日期：2007.6.4

  racemic-N-protected-β,γ-unsaturated α-amino acid thioesters were found to be substrates for the subtilisin-catalysed hydrolysis to the corresponding acids. The D-enantiomer was continuously racemised in the presence of an organic base. The combined reactions in a biphasic system allowed the deracemisation of the amino acid derivatives based on a dynamic kinetic resolution. Excellent yields and enantioselectivities

  发现外消旋-N-保护的β，γ-不饱和α-氨基酸硫代酯的L-形式是枯草杆菌蛋白酶催化水解成相应酸的底物。D-对映体在有机碱的存在下连续消旋。在双相系统中的合并的反应允许基于动态动力学拆分使氨基酸衍生物脱氨。获得了优异的产率和对映选择性。
• [EN] 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL<br/>[FR] DÉRIVÉS D'OXAZOLIDINONE 3,4-DISUBSTITUÉE ET LEUR UTILISATION COMME INHIBITEURS DES CANAUX POTASSIQUES ACTIVÉS PAR LE CALCIUM
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014067861A1

  公开（公告）日：2014-05-08

  The invention provides compounds having the general formula I wherein n, R1, R2a, R2b, R3a and R3b are as herein defined., composition comprising the compounds and methods of using the compounds.

  这项发明提供了具有一般式I的化合物，其中n、R1、R2a、R2b、R3a和R3b的定义如本文所述。包括这些化合物的组合物以及使用这些化合物的方法。